References
Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med. 2007;357:2601–14.
Fishman JA. Prevention of infection caused by Pneumocystis carinii in transplant recipients. Clin Infect Dis. 2001;33:1397–405.
Martin SI, Fishman JA; AST Infectious Diseases Community of Practice. Pneumocystis pneumonia in solid organ transplant recipients. Am J Transplant. 2009;9:S227–33.
Orr KE, Gould FK, Short G, et al. Outcome of Toxoplasma gondii mismatches in heart transplant recipients over a period of 8 years. J Infect. 1994;29:249–53.
Neff RT, Jindal RM, Yoo DY, Hurst FP, Agodoa LY, Abbott KC. Analysis of USRDS: incidence and risk factors for Pneumocystis jiroveci pneumonia. Transplantation. 2009;88:135–41.
Di Cocco P, Orlando G, Bonanni L, et al. A systematic review of two different trimetoprim–sulfamethoxazole regimens used to prevent Pneumocystis jirovecii and no prophylaxis at all in transplant recipients: appraising the evidence. Transplant Proc. 2009;41:1201–3.
Rubin RH. Infection in the organ transplant recipient. In: Rubin RH, Young LS, editors. Clinical approach to infection in the compromised host. 3rd ed. New York: Plenum Publishing; 1994. p. 629–705.
Fox BC, Sollinger HW, Belzer FO, Maki DG. A prospective, randomized, double-blind study of trimethoprim–sulfamethoxazole for prophylaxis of infection in renal transplantation: clinical efficacy, absorption of trimethoprim–sulfamethoxazole, effects on the microflora, and the cost–benefit of prophylaxis. Am J Med. 1990;89:255–74.
Yazaki H, Goto N, Uchida K, Kobayashi T, Gatanaga H, Oka S. Outbreak of Pneumocystis jiroveci pneumonia in renal transplant recipients: P. jiroveci is contagious to the susceptible host. Transplantation. 2009;88:380–5.
Arend SM, Westendorp RG, Kroon FP, et al. Rejection treatment and cytomegalovirus infection as risk factors for Pneumocystis carinii pneumonia in renal transplant recipients. Clin Infect Dis. 1996;22:920–5.
De Castro N, Xu F, Porcher R, Pavie J, Molina JM, Peraldi MN. Pneumocystis jirovecii pneumonia in renal transplant recipients occurring after discontinuation of prophylaxis: a case–control study. Clin Microbiol Infect. 2010;16:1375–7.
Derouin F, Pelloux H; ESCMID Study Group on Clinical Parasitology. Prevention of toxoplasmosis in transplant patients. Clin Microbiol Infect. 2008;14:1089–101.
Martina MN, Cervera C, Esforzado N, et al. Toxoplasma gondii primary infection in renal transplant recipients. Two case reports and literature review. Transpl Int. 2011;24:e6–12.
Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia. 2007;21:1387–94.
Schwartz JJ, Ishitani MB, Weckwerth J, Morgenstern B, Milliner D, Stegall MD. Decreased incidence of acute rejection in adolescent kidney transplant recipients using antithymocyte induction and triple immunosuppression. Transplantation. 2007;84:715–21.
Schooley RT, Hirsch MS, Colvin RB, et al. Association of herpesvirus infections with T-lymphocyte-subset alterations, glomerulopathy, and opportunistic infections after renal transplantation. N Engl J Med. 1983;308:307–13.
Cheeseman SH, Henle W, Rubin RH, et al. Epstein–Barr virus infection in renal transplant recipients. Effects of antithymocyte globulin and interferon. Ann Intern Med. 1980;93:39–42.
Issa NC, Fishman JA. Infectious complications of antilymphocyte therapies in solid organ transplantation. Clin Infect Dis. 2009;48:772–86.
Louis S, Audrain M, Cantarovich D, et al. Long-term cell monitoring of kidney recipients after an antilymphocyte globulin induction with and without steroids. Transplantation. 2007;83:712–21.
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Malhotra, P., Rai, S.D. & Hirschwerk, D. Duration of prophylaxis with trimethoprim–sulfamethoxazole in patients undergoing solid organ transplantation. Infection 40, 473–475 (2012). https://doi.org/10.1007/s15010-012-0277-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15010-012-0277-y